Literature DB >> 12419780

Despite concerns, FDA panel backs EGFR inhibitor.

Renee Twombly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12419780     DOI： 10.1093/jnci/94.21.1596

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Signaling pathways in NSCLC as a predictor of outcome and response to therapy.

Authors:  Anjali K Gupta; Daniel E Soto; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Stephen M Hahn; Mitchell Machtay; Ruth J Muschel; W Gillies McKenna
Journal:  Lung       Date:  2004       Impact factor: 2.584

2.  Regioselective Palladium-Catalyzed Cross-Coupling Reactions of 2,4,7-Trichloroquinazoline.

Authors:  Peter Wipf; Kara M George
Journal:  Synlett       Date:  2010-03-01       Impact factor: 2.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.